| ￥3500 | |
| Z04969-100 | |
|
|
|
|
|
|
|
|
|
| Species | HBV | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 17.81 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 17.81 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of Hepatitis B Virus (HBV) (ayw/France/Tiollais/1979) Capsid, His, HBV is greater than 95% as determined by SEC-HPLC. »
Hepatitis B Virus (HBV) (ayw/France/Tiollais/1979) Capsid, His, HBV on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Hepatitis B virus (HBV) core protein, the building block of the HBV capsid, plays multiple roles in viral replication, and is an attractive target for development of antiviral agents with a new mechanism of action. |
| Synonyms | Capsid; Core antigen; Core; HBcAg; p21.5; C |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
